Not medical advice. I am a software engineer, not a physician. This page documents my own protocol and the research I read while building it. Talk to a qualified clinician before changing your supplementation, diet or any treatment. Lab reference ranges quoted here vary by laboratory and by individual.
Affiliate disclosure: the iHerb links on this page carry a referral code and pay me a commission if you buy. It does not change your price, and I do not link anything I do not use myself.
The skeletal system is far more than a structural framework. The 206 bones of the adult skeleton provide mechanical support, protect vital organs, enable movement through muscle attachment, store 99% of the body's calcium, and house bone marrow where blood cells are produced. Bone is a living, dynamic tissue that constantly remodels itself — osteoblasts build new bone while osteoclasts break down old bone. After age 30, bone resorption gradually exceeds formation, leading to progressive bone density loss that can culminate in osteoporosis if not addressed through nutrition, exercise, and supplementation.
Bone health is assessed through a combination of blood markers (which reveal the nutritional inputs for bone formation) and imaging (which measures actual bone density).
| Test | What It Detects | Link |
|---|---|---|
| Calcium (Serum) | Blood calcium levels; tightly regulated by parathyroid hormone. Low dietary calcium forces bone resorption to maintain blood levels | Lab Tests |
| Vitamin D (25-OH) | Essential for calcium absorption; deficiency (<30 ng/mL) dramatically reduces calcium uptake regardless of intake. Optimal: 40-60 ng/mL | Lab Tests |
| Vitamin K (if available) | Vitamin K2 activates osteocalcin (the protein that binds calcium into bone matrix). Without K2, calcium may deposit in arteries instead of bones | Lab Tests |
| DEXA Scan (Bone Densitometry) | Gold-standard imaging that measures bone mineral density (BMD) at hip and spine. T-score above -1.0 is normal; below -2.5 is osteoporosis | Lab Tests |
Bone health requires a synergistic trio: calcium provides the mineral substrate, vitamin D drives absorption, and vitamin K2 directs calcium into bone rather than soft tissue.
| Supplement | How It Helps | Link |
|---|---|---|
| Calcium Citrate (3x/day) | Better absorbed than calcium carbonate; does not require stomach acid. Split into 3 doses (max 500 mg per dose) because the body cannot absorb more than ~500 mg at once. | Calcium Citrate |
| Vitamin D3 + K2 | D3 increases calcium absorption from 10-15% to 30-40%. K2 (MK-7 form) activates osteocalcin to incorporate calcium into bone matrix and activates MGP to prevent arterial calcification. | Vitamin D3 + K2 |
| Magnesium | Required for vitamin D activation and PTH regulation. Over 60% of body magnesium is stored in bone. Deficiency accelerates bone loss independently of calcium status. | Magnesium Glycinate |
| Collagen Peptides | Provides the structural protein matrix (type I collagen) that gives bone its flexibility and tensile strength. Bones are ~35% collagen by weight. | Collagen Peptides |
| MSM | Provides bioavailable sulfur for connective tissue synthesis and supports collagen cross-linking in bone matrix. | MSM |
The D3+K2 synergy: Taking vitamin D without K2 increases calcium absorption but does not ensure it reaches bone. K2 activates two critical proteins: osteocalcin (binds calcium to bone) and matrix GLA protein (prevents calcium from depositing in arteries). Always take D3 and K2 together.
FDA qualifies BMD as a fracture surrogate endpoint. In December 2025, the FDA qualified total hip bone mineral density (BMD) measured by DXA as an acceptable surrogate endpoint for fractures in phase 3 osteoporosis drug trials. This landmark decision, based on the SABRE Project analyzing 52 clinical trials with over 160,000 participants, will accelerate the approval of new osteoporosis medications by allowing BMD improvements to demonstrate efficacy rather than waiting years for fracture outcomes. For patients, this means faster access to novel therapies.
Sequential therapy now standard: anabolic-first for high-risk patients. Updated 2025 treatment guidelines increasingly recommend starting with potent anabolic therapies (romosozumab or teriparatide) followed by antiresorptive agents (bisphosphonates or denosumab) for patients with 3-year fracture risk above 10%. This "build bone first, then protect it" approach produces significantly greater bone density gains than the traditional antiresorptive-first strategy. Emerging therapies targeting cathepsin K and sclerostin offer new mechanisms, while miRNA biomarkers (such as miR-203a) show promise for predicting fracture risk more accurately than BMD alone.